Advanced Breast Cancer Drug Eribulin Rejected by NICE

by Kathy Jones on  November 18, 2011 at 8:30 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

British health regulator National Institute for Health and Clinical Excellence (NICE) has issued a final draft rejecting the prescription of breast cancer drug eribulin by the NHS for treating patients who have advanced breast cancer.
 Advanced Breast Cancer Drug Eribulin Rejected by NICE
Advanced Breast Cancer Drug Eribulin Rejected by NICE

The draft revealed that while the drug could extend patients' lives by 2.7 months on average, it came with a number of side effects, such as anemia, fatigue and hair loss, which other treatments did not have.

"Although the evidence presented to the independent advisory committee indicated that eribulin may help some patients live for a little longer, it also caused more undesirable side effects than other treatments already available, and the effects on health-related quality of life had not been adequately assessed", chief executive of NICE, Sir Andrew Dillon said.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Women and Cancer Drug Toxicity Breast Biopsy Pagets disease of the breast Mastitis Cancer and Homeopathy Signature Drug Toxicity Breast Cancer Facts Cancer Facts Cancer 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive